Calcium antagonists and multi‐infarct dementia: A trial involving sequential NMR and psychometric assessment
Besson JAO., Palin AN., Ebmeier KP., Eagles JM., Smith FW.
A double‐blind placebo‐controlled trial of the calcium antagonist Nimodipine in 10 patients with multi‐infarct dementia (MID) shows that there is no improvement when compared with 10 patients on placebo assessed by clinical ratings and sequential NMR imaging. The value of repeated NMR imaging in measuring changes in MID is described. Copyright © 1988 John Wiley & Sons, Ltd.